Marathon Freedom Fund SP Fund Fact Sheet Class A - April 2015

Investment ObjectiveMarathon Freedom Fund SP is a global equity fund that seeks to offer clients the benefits from investment techniques which are typically exclusive to large investment Funds.

The Fund is medium risk and aims to provide capital growth but in a balanced manner by employing Warren Buffett’s ‘Focus Investing’ approach. This involves investing in equities from the perspective of buying into a business which is well run, has a distinct marketing edge and has a high probability of above average performance.

The focus is currently on the global markets where we believe more opportunities exist with a broader mandate.

Cumulative performance % (in denominated currency)

1 month 3 months 1 year 3 years Since launch Launch date

CLASS A -0.04 10.72 160.15 - 135.92 May 2013

Calendar year performance % (in denominated currency)

2009 2010 2011 2012 2013 2014 2015 YTD

CLASS A - - - - -5.46 125.46 12.50%

Top holdings (as at 30 April 2015)

Holdings Sector Region Holdings

Apple Consumer Goods US 27% Gilead Sciences Inc. Healthcare US 22% Boston Beer Co Consumer Goods US 22% Union Pacific Corp Services US 9% Schlumberger Ltd Basic Materials US 8% Micron Technology Inc Technology US 6% PUT Boston Beer Co Consumer Goods US 6%

30000

25000

20000

15000

USD 10,000 initial

investment

USD 23,592 (Growth of 123.6%)

Disclaimer:

The above graph is for ‘illustrative purposes’ only and should not be construed as a guide to future growth.

The graph below represents the growth of a USD10,000 investment.

Fund details and data at a glance

Minimum Subscription: USD 25,000 Subsequent Investment Minimum: USD 1,000 Initial Fee: Up to 5% Annual Management Fee: 2% Performance Fee: 25% (hurdle rate 5%) Dealing Restriction: Experienced Investors Asset Manager: Pathway Asset Management Administrator: Trust Admin UK Custodian: JP Morgan Legal Advisor: Harneys Cayman Auditors: PKF (Cayman) Dealing/Pricing: Monthly Dealing Day: 1st day of the month Launch Date: May 2013 Date: 30 April 2015 Denominated currency & NAV per unit: USD 235.92 SEDOL/ISIN code: KYG674931251

Performance Review

April was a pretty flat month for the major stock market indices. On average the US indices grew 1.1% while the major European indices were down 1.0%. On the other hand the Asian markets performed healthily with an average growth of 10%.

These indicators are a reflection of what is happening in the world economies today. US markets tend to portray modest growth; the European economies are suffering from the effects of the financial strain of Greek debt woes. The Asian economies continue to have expansive growth though being a risk on investment region.

During the month we added Gilead science Inc. (GILD) on a downward dip and that has paid off handsomely. Gilead is one of the leading biopharmaceutical manufacturers of antiviral drugs for the treatment of the human immunodeficiency virus (HIV) as well as a leader in producing liver disease drugs to fight hepatitis B and C viruses. The efficacy of their liver disease drug (Harvoni) is said to have 96- 99% cure rate in just 12 weeks of therapy and has been the driving force behind their recent stock price ascent. We believe we bought at an opportune time and are poised to benefit from this future growth.

In conclusion; we will maintain a cautious outlook for May and June as these months are considered to be the selling months, where trading activity is based on seasonal “emotional” selling rather than analytical and empirical information of the equity markets. Similarly if any buying opportunities should present themselves we will acquire appropriately.

Asset Manager: Pathway Asset ManagementDirect Line: +44 (0) 203 755 3457Dealing Fax: +44 (0) 207 170 4001Email: enquiries@pathwayam.proAddress: Winchester House 259-269 Old Marylebone Rd, London, NWI 5RA

Olympic Wealth Fund SPC

This fact sheet and the information it contains has been produced by Olympic Wealth Management in conjunction with the Fund Manager, Pathway Asset Management with the aim of providing information to current and prospective investors to the Fund.

It should be noted that this fact sheet itself, does not represent an offering and should be read in conjunction with the Fund’s Offering Memorandum which provides detailed information on the Fund including investment type, investment strategy and leverage limits. Please note that past performance does not guarantee future payments and that the value of the income derived from investments may fluctuate up or down and investors into the Fund may not get back their original investment.

Further information regarding Marathon Freedom Fund SP Fund can be obtained from the Offering Memorandum document available on our website: www.olympicwealth.com

Disclaimer

Class A: Investment performance since inception in May 2013

Class A: Growth of a USD10,000 investment since inception in May 2013

20000 18000 16000 14000 12000 10000

USD 10,000 initial

investment

CLASS A: Growth of a USDl0,000 investment since inception in July 2011

USD 18,981 (Growth of 90%)